Shares of Ovid Therapeutc (NASDAQ:OVID) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price objective of $21.00 for the company and are anticipating that the company will post ($0.39) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Ovid Therapeutc an industry rank of 99 out of 265 based on the ratings given to related companies.
OVID has been the subject of a number of research analyst reports. Cowen and Company initiated coverage on Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating for the company. JMP Securities initiated coverage on Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating and a $26.00 price objective for the company. William Blair initiated coverage on Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating for the company. Finally, Citigroup Inc. initiated coverage on Ovid Therapeutc in a report on Tuesday, May 30th. They set a “buy” rating and a $21.00 price objective for the company.
Large investors have recently modified their holdings of the stock. Victory Capital Management Inc. bought a new stake in shares of Ovid Therapeutc during the second quarter valued at about $1,374,000. Jennison Associates LLC bought a new stake in shares of Ovid Therapeutc during the second quarter valued at about $6,739,000. Bank of New York Mellon Corp bought a new stake in shares of Ovid Therapeutc during the second quarter valued at about $135,000. Alps Advisors Inc. bought a new stake in shares of Ovid Therapeutc during the second quarter valued at about $233,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Ovid Therapeutc during the second quarter valued at about $153,000. Institutional investors and hedge funds own 0.01% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/08/08/ovid-therapeutc-ovid-receives-average-recommendation-of-from-analysts.html.
Shares of Ovid Therapeutc (OVID) traded down 3.85% during mid-day trading on Friday, hitting $7.24. The company’s stock had a trading volume of 22,885 shares. The company has a 50-day moving average of $10.44 and a 200 day moving average of $11.72. Ovid Therapeutc has a 1-year low of $7.15 and a 1-year high of $15.93. The company’s market cap is $178.11 million.
Ovid Therapeutc (NASDAQ:OVID) last issued its quarterly earnings data on Tuesday, June 13th. The company reported ($3.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by $2.61. On average, analysts expect that Ovid Therapeutc will post ($3.27) EPS for the current year.
Ovid Therapeutc Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Get a free copy of the Zacks research report on Ovid Therapeutc (OVID)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.
